These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 20415625)

  • 1. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
    Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
    Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
    Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
    Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intravitreal injection of triamcinolone for exudative age-related macular degeneration.
    Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B
    Ophthalmic Res; 2006; 38(6):324-8. PubMed ID: 17047404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
    Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration.
    Tao Y; Libondi T; Jonas JB
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):79-83. PubMed ID: 20148662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
    Lim JW; Lee HK; Shin MC
    Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.
    Aggio FB; Farah ME; Silva WC; Melo GB
    Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):215-20. PubMed ID: 17139490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
    Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
    Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
    Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
    Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
    Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
    Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
    Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
    Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.